

**Table 1. Baseline characteristics of patients treated with ruxolitinib**

Characteristics	All Patients (N=287)
Age – mean (IQR)	54 ± 14
Sex – no. (%)	
Male	185 (64.5)
Female	102 (35.5)
Comorbidities – no. (%)	
Obesity – BMI ≥30	118 (41)
Hypertension	104 (36)
Type 2 Diabetes	87 (30)
Chronic pneumopathy	13 (4.5)
Chronic cardiopathy	9 (3.1)
Invasive Mechanical Ventilation	59 (20.6)
Vasopressor use	26(9.1)
Body Mass Index – no.	30 ± 6
Charlson Comorbidity Index – mean (range)	0 (0-7)
Laboratory Values –	
Hemoglobin - g/dL	13 ± 0.75
Leucocytes - x10 <sup>9</sup> /L	11.5 ± 4.8
Lymphocytes - cells x10 <sup>9</sup> /L	1.1 ± 0.32
Neutrophils - cells x10 <sup>9</sup> /L	8 ± 1.5
Platelets - cells x10 <sup>9</sup> /L	337 ± 39
Glucose - mg/dL	133 ± 22
Creatinine – mg/dL	1.14 ± 1.95
Albumin - mg/dL	2.9 ± 0.34
Erythrocyte sedimentation rate - mm/hr	31 ± 6
C-reactive protein - mg/dL	44.84 ± 80.11
Procalcitonin - ng/mL	1.27 ± 3.95
Lactate Dehydrogenase - UI/L	395 ± 132
Ferritin - ng/dL	939 ± 278
Fibrinogen - mg/dL	486 ± 120
D-dimer - ng/mL	2593.76 ± 4762.75